Phillips Anne M.
Transaction: 06/26/2026
BUY
Change
+6,000
Price
$35.08
Filing
06/29/2026
Type
BUY
vTv Therapeutics Inc.
VTVT • Biotechnology
$33.35
▼ -0.12 (-0.36%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$413.85M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 13.54Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:56 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$33.35
Change-0.36%
Shares Out12.41M
Market Cap$413.85M
Enterprise Value$327.21M
52W Range14.55 - 44.00
Beta0.29
P/E-87.02
P/S11.23
P/B5.26
P/FCF-54.40
EV/Sales8.88
Price$33.35
Change-0.36%
Shares Out12.41M
Market Cap$413.85M
Enterprise Value$327.21M
52W Range14.55 - 44.00
Beta0.29
P/E-87.02
P/S11.23
P/B5.26
P/FCF-54.40
EV/Sales8.88
EV/EBITDA-45.06
EV/FCF-43.01
Earnings Yield-1.15%
FCF Yield-1.84%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio13.54
Quick Ratio13.54
Revenue 5Y-100.00%
Target$42.00
Target Upside25.94%
Target Median$42.00
Target Range42.00 - 42.00
Volume49.42K
Avg Volume65.60K
EPS Surprise1.31
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
60/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 13.54Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 14 analyst votes · 2026-09-05
75/100
Bullish
Bullish
7
Hold
7
Bearish
0
Price Target
2026-08-13
Low
$42.00
Mean
$42.00
Median
$42.00
High
$42.00
Insider Transactions
Recent executive and insider activity
Al-Marzooqi Fahed
Transaction: 06/26/2026
BUY
Change
+6,000
Price
$35.08
Filing
06/29/2026
Type
BUY
AKKARAJU SRINIVAS
Transaction: 06/26/2026
BUY
Change
+6,000
Price
$35.08
Filing
06/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Phillips Anne M. | BUY | +6,000 | $35.08 | 06/26/2026 | 06/29/2026 |
| Al-Marzooqi Fahed | BUY | +6,000 | $35.08 | 06/26/2026 | 06/29/2026 |
| AKKARAJU SRINIVAS | BUY | +6,000 | $35.08 | 06/26/2026 | 06/29/2026 |
| SPIEGELMAN DANIEL K | BUY | +6,000 | $35.08 | 06/26/2026 | 06/29/2026 |
| BAKER BROS. ADVISORS LP | BUY | +6,000 | $35.08 | 06/26/2026 | 06/29/2026 |
| SEKHRI PAUL J | BUY | +140,000 | $36.92 | 02/17/2026 | 02/18/2026 |
| Tung Michael Stephen | BUY | +44,969 | $36.92 | 02/17/2026 | 02/18/2026 |
| AKKARAJU SRINIVAS | BUY | +106,000 | $15.27 | 09/22/2025 | 09/25/2025 |
| AKKARAJU SRINIVAS | BUY | +877,214 | $0.01 | 09/22/2025 | 09/25/2025 |
| AKKARAJU SRINIVAS | BUY | +983,214 | $22.71 | 09/22/2025 | 09/25/2025 |
| BAKER BROS. ADVISORS LP | BUY | +4,308 | $15.27 | 09/03/2025 | 09/05/2025 |
| BAKER BROS. ADVISORS LP | BUY | +221,452 | Not reported | 09/03/2025 | 09/05/2025 |
| BAKER BROS. ADVISORS LP | BUY | +217,144 | $0.01 | 09/03/2025 | 09/05/2025 |
| AKKARAJU SRINIVAS | BUY | +655,523 | $22.71 | 09/03/2025 | 09/05/2025 |
| AKKARAJU SRINIVAS | BUY | +655,523 | $0.01 | 09/03/2025 | 09/05/2025 |
| Al-Marzooqi Fahed | BUY | +4,000 | $16.59 | 06/10/2025 | 06/12/2025 |
| Phillips Anne M. | BUY | +4,000 | $16.59 | 06/10/2025 | 06/12/2025 |
| AKKARAJU SRINIVAS | BUY | +4,000 | $16.59 | 06/10/2025 | 06/12/2025 |
| SPIEGELMAN DANIEL K | BUY | +4,000 | $16.59 | 06/10/2025 | 06/12/2025 |
| BAKER BROS. ADVISORS LP | BUY | +4,000 | $16.59 | 06/10/2025 | 06/12/2025 |